Tags

Type your tag names separated by a space and hit enter

Argentine hemorrhagic fever vaccines.
Hum Vaccin. 2011 Jun; 7(6):694-700.HV

Abstract

Argentine hemorrhagic fever (AHF), an acute disease caused by Junin virus (JUNV, Arenaviridae), has been an important issue to public health in Argentina since the early 1950s. The field rodent Calomys musculinus is JUNV natural reservoir and human disease is a consequence of contact with infected rodents. A steady extention of AHF endemic area is being observed since the first reports of the disease. Important achievements have been made in: (a) improvement of methods for the etiological diagnosis; (b) implementation and validation of therapeutical measures; (c) development of vaccines to protect against AHF. Reference is made to different research strategies used to obtain anti-AHF vaccines in the past and anti-arenaviral diseases in the present. Information is updated on features and field performance of Candid #1 vaccine, a live attenuted vaccine currently used to prevent AHF. This vaccine was developed through a joint international effort that envisioned it as an orphan drug. With transferred technology, Argentine government was committed to be Candid #1 manufacturer and to register this vaccine as a novel medical product under the Argentine regulatory authority. Candid #1 vaccine is the first one used to control an arenaviral hemorrhagic fever, the first live viral vaccine to be manufactured and registered in Argentina, reaching its target population through governmental effort.

Authors+Show Affiliations

Instituto Nacional de Enfermedades Virales Humanas Dr JI Maiztegui, ANLIS, Provincia de Buenos Aires, Argentina. anaambrosio@yahoo.com.arNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21451263

Citation

Ambrosio, Ana, et al. "Argentine Hemorrhagic Fever Vaccines." Human Vaccines, vol. 7, no. 6, 2011, pp. 694-700.
Ambrosio A, Saavedra M, Mariani M, et al. Argentine hemorrhagic fever vaccines. Hum Vaccin. 2011;7(6):694-700.
Ambrosio, A., Saavedra, M., Mariani, M., Gamboa, G., & Maiza, A. (2011). Argentine hemorrhagic fever vaccines. Human Vaccines, 7(6), 694-700.
Ambrosio A, et al. Argentine Hemorrhagic Fever Vaccines. Hum Vaccin. 2011;7(6):694-700. PubMed PMID: 21451263.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Argentine hemorrhagic fever vaccines. AU - Ambrosio,Ana, AU - Saavedra,Maria, AU - Mariani,Mauricio, AU - Gamboa,Graciela, AU - Maiza,Andrea, Y1 - 2011/06/01/ PY - 2011/4/1/entrez PY - 2011/4/1/pubmed PY - 2011/12/21/medline SP - 694 EP - 700 JF - Human vaccines JO - Hum Vaccin VL - 7 IS - 6 N2 - Argentine hemorrhagic fever (AHF), an acute disease caused by Junin virus (JUNV, Arenaviridae), has been an important issue to public health in Argentina since the early 1950s. The field rodent Calomys musculinus is JUNV natural reservoir and human disease is a consequence of contact with infected rodents. A steady extention of AHF endemic area is being observed since the first reports of the disease. Important achievements have been made in: (a) improvement of methods for the etiological diagnosis; (b) implementation and validation of therapeutical measures; (c) development of vaccines to protect against AHF. Reference is made to different research strategies used to obtain anti-AHF vaccines in the past and anti-arenaviral diseases in the present. Information is updated on features and field performance of Candid #1 vaccine, a live attenuted vaccine currently used to prevent AHF. This vaccine was developed through a joint international effort that envisioned it as an orphan drug. With transferred technology, Argentine government was committed to be Candid #1 manufacturer and to register this vaccine as a novel medical product under the Argentine regulatory authority. Candid #1 vaccine is the first one used to control an arenaviral hemorrhagic fever, the first live viral vaccine to be manufactured and registered in Argentina, reaching its target population through governmental effort. SN - 1554-8619 UR - https://www.unboundmedicine.com/medline/citation/21451263/Argentine_hemorrhagic_fever_vaccines_ L2 - http://www.diseaseinfosearch.org/result/3317 DB - PRIME DP - Unbound Medicine ER -